Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors

Diagnostic Pathology

Lobna S Shash¹  Nehal A Radwan¹  Iman H Hewedi¹ 

[1] Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

关键词: STUMP;    Leiomyosarcoma;    uterine smooth muscle tumor;    p53;    PR;   

Others  :  808175
DOI  :  10.1186/1746-1596-7-1

 received in 2011-12-06, accepted in 2012-01-05,  发布年份 2012

【 摘 要 】

Background

The diagnosis of uterine smooth muscle tumors depends on a combination of microscopic features. However, a small number of these tumors still pose difficult diagnostic challenges.

Aim

To investigate progesterone receptor (PR) and p53 expression in leiomyomas (LMs), atypical leiomyomas (ALMs), smooth muscle tumors of uncertain malignant potential (STUMP), and leiomyosarcomas (LMSs) and to evaluate the potential utility of the selected immunohistochemical markers in differentiating these tumors.

Materials and methods

Immunohistochemical expression of PR and p53 was investigated in 41 uterine smooth muscle tumors comprising: 15 LMS, 4 STUMP, 6 ALM and 16 LM. Quantitative evaluation of PR and p53 expression was graded on a scale from 0 to 3+.

Results

Leiomyosarcomas showed reduced PR expression. All LMs as well as ALMs and STUMP were stained intensely for PR. Conversely, LMS was strongly stained with p53, while the three non-sarcomatous groups (STUMP, ALM, LM) were either entirely negative or weakly stained for p53. Regarding both PR and p53 expression, the difference between the LMS group and the three non-sarcomatous groups was highly significant (p < 0.001). Combined high PR - low p53 expression was seen in all the 26 examined cases of the non-sarcomatous group including the STUMP cases and none of the LMS cases. Therefore, it represents a "benign" profile with 100% specificity in diagnosis of a non-sarcomatous tumor.

Conclusion

Immunohistochemistry for PR and p53 is valuable as an adjunct tool to morphological assessment of problematic uterine smooth muscle tumors.

Virtual Slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1033065653646058 webcite.

【 授权许可】

   
2012 Hewedi et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Zaloudek CJ, Hendrickson MR, Soslow RA: Mesenchymal tumors of the uterus. In Blaustein's Pathology of the Female Genital Tract. 6th edition. Edited by R. Kurman RJ, Ellenson LH, Ronnett BM. Springer New York; 2011:453-527.
• [2]Rammeh-Rommani S, Mokni M, Stita W, Trabelsi A, Hamissa S, Sriha B, Tahar-Yacoubi M: J Gynecol Obstet Biol Reprot. 2005, 34:568-7.
• [3]Ünver NU, Acikalin MF, Öner Ü, Ciftci E, Ozalp SS, Colak E: Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors. Arch Gynecol Obstet 2011, 284(2):483-90.
• [4]O'neill CI, Mcbride HA, Connolly LE, Mccluggage WG: Histopathology. 2007, 50:851-8.
• [5]Gökaslan H, Turkeri L, Kavak ZN, Eren F, Sismanoglu A, Ilvan S, et al.: Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. Gynecol Obstet Invest 2005, 59:36-40.
• [6]Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Mayerhofer K: Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors. Fertil Steril 2004, 81:1062-6.
• [7]Mittal K, Demopoulos RI: MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol 2001, 32:984-7.
• [8]Zhai YL, Kobayashi Y, Mori A, Orii A, Nikaido T, Konishi I, et al.: Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol 1999, 18:20-8.
• [9]Mayerhofer K, Obermair A, Windbichler G, Petru E, Kaider A, Hefler L, et al.: Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 1999, 74:196-201.
• [10]Al-Nafussi A: Uterine smooth-muscle tumours: practical approach to diagnosis. Curr Diagn Pathol 2004, 10:140-56.
• [11]Watanabe K, Suzuki T: Uterine leiomyoma versus leiomyosarcoma: a new attempt at differential diagnosis based on their cellular characteristics. Histopathology 2006, 48:563-8.
• [12]Petrovic D, Babic D, Forko JI, Martinac I: Expression of Ki-67, p53 and progesterone receptors in uterine smooth muscle tumors: diagnostic value. Coll Antropol 2010, 34(1):93-7.
• [13]Buttram VC Jr, Reiter RC: Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981, 36:433-45.
• [14]Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T: Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989, 160:637-41.
• [15]Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K: Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res 2003, 23:729-32.
• [16]Soper JT, McCarty KS Jr, Creasman WT, McCarty KS Sr, Clarke-Pearson DL: Cytoplasmic estrogen and progesterone receptor content of uterine sarcomas. Am J Obstet Gynecol 1984, 150:342-8.
• [17]Akhan SE, Yavuz E, Tecer A, yibozkurt CA, Topuz S, Tuzlalı S, et al.: The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas: A clinicopathologic study. Gynecol Oncol 2005, 99:36-42.
• [18]Zalondex CJ, Hendricksen CJ: Mesenchymal tumors of the uterus. In Blaustein's pathology of the female genital tract. fifth edition. Edited by Kurman RJ. Spinger, New York; 2002:561-615.
• [19]Westhof G, Bader W, Greiner-Mai E, Hartzmann W: Comparison of cytosolic p53 protein levels in the female genital tract and breast, and their tumors. Tumor Biol 2000, 21:123-134.
• [20]De Vos S, Wilczynski SP, Fleishhacker M, Koeffler P: p53 alterations in uterine leiomyosarcomas versus leiomyomas. Gynecol Oncol 1994, 54:205-208.
• [21]Hong T, Schimada Y, Uchida S, Itami A, Li Z, Ding Y, Kaganoi J, Komoto I, Sakurai T, Imamura M: Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int J Mol Med 2001, 8:141-148.
• [22]Jeffers MD, Farquharson MA, Richmond JA, McNicol AM: p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumors of the uterine corpus. J Pathol 1995, 177:65-70.
• [23]Nordal RR, Kristensen GB, Stenwig AE, Trope CG, Nesland JM: Immunohistochemical analysis of p53 protein in uterine sarcomas. Gynecol Oncol 1998, 70:45-48.
• [24]Wang M, Xu Y, Zhang T: Smooth muscle neoplasms of the uterus - A 51 cases study. Zhonghua Bing Li Xue Za Zhi 1996, 25:263-265.
• [25]Kayser K, Zink S, Schneider T, Dienemann H, Andre S, Kaltner H, Schuring MP, Zick Y, Gabius HJ: Benign metastasizing leiomyoma of the uterus: Documentation of clinical, immunohistochemical and lectin-histochemical data of ten cases. Virchows Arch 2000, 473:284-292.